Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
During today’s Big Game, viewers will have learned that the much-talked about sequel of an ʼ80s movie, “Dundee: The Son of a Legend Returns Home”, is not a sequel at all. It is actually an elaborate, star-studded advertising campaign aimed at attracting more travelers to visit Australia.
Tourism Australia, the government agency responsible for attracting international visitors to Australia, has revealed it is behind the major US marketing campaign.
Over the past two weeks, excitement for the new Crocodile Dundee movie has been steadily building. Imitating a traditional studio promotional campaign—using PR, social, digital, OOH and the release of four teaser films—anticipation for the new film was widely reported in People, Buzzfeed, Daily Mail, Good Morning America, and the Hollywood Reporter, among others.
To view the multimedia release go to:
https://www.multivu.com/players/English/8268251-tourism-australia-dundee/
Fisher-Price, Inc., one of the world's leading infant and preschool toy manufacturers and a subsidiary of Mattel, Inc., today released a short film entitled Wishes for Baby, marking the official launch of the Best Possible Start marketing campaign. Directed by award-winning documentarian Patrick Creadon, and filmed with real parents around the world on New Year-s Day and the final days of December 2014, this short film captures the incredible love and hopes all parents share for their children during those first moments after their baby is born.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7411351-fisher-price-best-possible-start/
Video oficial de la nueva version de ¨TRAS DE TUS PASOS¨ incluida en el material ¨Xeronimo Deluxe.¨ Artista: XERONIMO CD: Xeronimo Deluxe Visitanos en nuestro canal de youtube http://www.youtube.com/xeronimoplay PARA MAS INFO DEL ARTISTA: Visita Nuestra pagina web en: http://www.xeronimomusica.com http://www.facebook.com/xeronimoficial http://www.twitter.com/xeronimomusica
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
